The role of osimertinib in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer

Documenti analoghi

• Central nervous system activity of first-line osimertinib in epidermal growth factor receptor-mutant advanced non-small cell lung cancer
  di: Liam, Chong-Kin
  Pubblicazione: (2019)
• Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer
  di: Liam, Chong-Kin
  Pubblicazione: (2017)
• Current role and future direction of osimertinib in epidermal growth factor receptor-mutant non-small cell lung cancer
  di: Jeong, Byeong-Ho, et al.
  Pubblicazione: (2019)
• Impact of clinical features on the efficacy of osimertinib treatment in epidermal growth factor receptor mutant non-small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors due to T790M mutation
  di: Liam, Chong-Kin, et al.
  Pubblicazione: (2019)
• Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer
  di: Gregorc, Vanesa, et al.
  Pubblicazione: (2018)